Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Stopped The study was terminated due to poor feasibility and lack of interest at the participating sites.

Conditions

• Multiple Myeloma
• Neoplasms
• Plasma Cells
• Paraproteinemias
• Blood Protein Disorders
• Hematologic Diseases
• Therapeutic Uses

Interventions

• DRUG: Lenalidomide

Sponsor

Celgene